Few experts can deal appropriately with metastatic bone tumors in the present situation. We developed a questionnaire about zoledronic acid for doctors with several specialties, and analyzed the differences in treatment strategy among various doctors retrospectively. Breast surgeons, have used zoledronic acid appropriately based on accurate knowledge, but it has been used inappropriately by doctors of other specialties due to lack of knowledge. Development of new treatment for metastatic bone tumors is awaited, but there is a possibility of inappropriate use as with zoledronic acid because of lack of knowledge and experience. So a medical team is necessary to provide the most recent knowledge of metastatic bone tumor and to enlighten other doctors.
|Number of pages||5|
|Journal||Japanese Journal of Cancer and Chemotherapy|
|Publication status||Published - 2010 Mar 6|
- Cancer board
- Metastatic bone tumor
- Zoledronic acid
ASJC Scopus subject areas